Cancer Research Institute
Clinical Trials
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma
The purpose of this study is to determine the side effects of TAB004 (investigational drug) when given alone or in combination with toripalimab (another investigational drug), to determine a reasonably safe amount (dose) of TAB ...
A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy
The aim of this study is to assess the safety and effectiveness of the study drug, TTAC-0001 to patients with recurrent glioblastoma which has progressed on bevacizumab treatment. Another aim is to measure the levels of TTAC-00 ...
A Nanotechnology-Enabled Blood Test for Cancer Detection and Diagnosis
The purpose of this study is to determine if a new blood test can be used for early detection of prostate and kidney cancer. The results of this study may be published in a peer-reviewed scientific journal by the research team. ...
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors.
The purpose of this study is to see if the study drug is safe and able to treat patients who have certain types of cancers, including solid tumors, triple negative breast cancer, pancreatic cancer, urothelial cancer, hepatocell ...
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advance Solid Refractory/Resistant Malignancies
You are being invited to take part voluntarily in this research study because you have a solid tumor that hasn’t responded to previous treatment or has spread to other parts of your body (metastatic), including ovarian, cervica ...
A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
Participants who have have relapsed (returning) and refractory (stopped responding to treatment) multiple myeloma (RRMM) will be invited to take part in this study. This study is being done to learn more about the drug AMG 701 ...
A Phase 2 trial of Nirogacestat in Patients with Recurrent Ovarian Granulosa
Cell Tumors
Cell Tumors
You are being asked to take part in a clinical research study because you have a rare type of ovarian cancer known as ovarian granulosa cell tumor (also known as sex cord-stromal tumor). A person who takes part in a research st ...
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
A study comparing VRd followed by ciltacabtagene autoleucel, versus VRd followed by Rd Therapy in Subjects with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy ...